165 related articles for article (PubMed ID: 27487812)
1. Thrombin Activable Fibrinolysis Inhibitor in Beta Thalassemia.
Chhikara A; Sharma S; Chandra J; Nangia A
Indian J Pediatr; 2017 Jan; 84(1):25-30. PubMed ID: 27487812
[TBL] [Abstract][Full Text] [Related]
2. Thrombin activatable fibrinolysis inhibitor (TAFI): relationship to hemostatic alteration in patients with beta-thalassemia.
Mokhtar GM; Matter RM; Shawki H; Abdel Aziz MM
Pediatr Hematol Oncol; 2010 Aug; 27(5):363-73. PubMed ID: 20670166
[TBL] [Abstract][Full Text] [Related]
3. Blood coagulation and fibrinolysis in patients with Cushing's syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels.
Erem C; Nuhoglu I; Yilmaz M; Kocak M; Demirel A; Ucuncu O; Onder Ersoz H
J Endocrinol Invest; 2009 Feb; 32(2):169-74. PubMed ID: 19411818
[TBL] [Abstract][Full Text] [Related]
4. [Relationship between plasma levels of thrombin activatable fibrinolysis inhibitor, plasminogen activator inhibitor-1 and tissue-type plasminogen activator and deep venous thrombosis in patients with systemic lupus erythematosus].
Liu YF; Hou N; Shi YJ; Li CX; Gao YJ; Liu LN
Zhonghua Yi Xue Za Zhi; 2023 Jun; 103(21):1638-1642. PubMed ID: 37248064
[No Abstract] [Full Text] [Related]
5. Increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels in patients with primary hyperparathyroidism.
Erem C; Kocak M; Nuhoglu I; Yilmaz M; Ucuncu O
Eur J Endocrinol; 2009 May; 160(5):863-8. PubMed ID: 19233920
[TBL] [Abstract][Full Text] [Related]
6. Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1.
Meltzer ME; Lisman T; de Groot PG; Meijers JC; le Cessie S; Doggen CJ; Rosendaal FR
Blood; 2010 Jul; 116(1):113-21. PubMed ID: 20385790
[TBL] [Abstract][Full Text] [Related]
7. Thalassemia major-- on the verge of bleeding or thrombosis?
Naithani R; Chandra J; Narayan S; Sharma S; Singh V
Hematology; 2006 Feb; 11(1):57-61. PubMed ID: 16522552
[TBL] [Abstract][Full Text] [Related]
8. The relationship among TAFI, t-PA, PAI-1 and F1 + 2 in type 2 diabetic patients with normoalbuminuria and microalbuminuria.
Chudý P; Kotuličová D; Staško J; Kubisz P
Blood Coagul Fibrinolysis; 2011 Sep; 22(6):493-8. PubMed ID: 21519232
[TBL] [Abstract][Full Text] [Related]
9. Thrombin activatable fibrinolysis inhibitor antigen levels are inversely correlated with plasminogen activator inhibitor-1 antigen levels in hyperthyroid patients.
Akinci B; Comlekci A; Yener S; Demir T; Ozcan MA; Bayraktar F; Yesil S
Endocr J; 2007 Aug; 54(4):593-9. PubMed ID: 17690487
[TBL] [Abstract][Full Text] [Related]
10. Hemostatic alterations in splenectomized and non-splenectomized patients with beta-thalassemia/hemoglobin E disease.
Tripatara A; Jetsrisuparb A; Teeratakulpisarn J; Kuaha K
Thromb Res; 2007; 120(6):805-10. PubMed ID: 17382994
[TBL] [Abstract][Full Text] [Related]
11. Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor and thrombomodulin levels in children with hypothyroidism.
Alioğlu B; Kılıç N; Şimşek E; Dallar Y
J Clin Res Pediatr Endocrinol; 2012 Sep; 4(3):146-50. PubMed ID: 22985614
[TBL] [Abstract][Full Text] [Related]
12. Thrombin-activatable fibrinolysis inhibitor in young patients with myocardial infarction and its relationship with the fibrinolytic function and the protein C system.
Zorio E; Castelló R; Falcó C; España F; Osa A; Almenar L; Aznar J; Estellés A
Br J Haematol; 2003 Sep; 122(6):958-65. PubMed ID: 12956767
[TBL] [Abstract][Full Text] [Related]
13. Active PAI-1 as marker for venous thromboembolism: case-control study using a comprehensive panel of PAI-1 and TAFI assays.
Bollen L; Peetermans M; Peeters M; Van Steen K; Hoylaerts MF; Declerck PJ; Verhamme P; Gils A
Thromb Res; 2014 Nov; 134(5):1097-102. PubMed ID: 25193405
[TBL] [Abstract][Full Text] [Related]
14. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity.
Erem C
Clin Endocrinol (Oxf); 2006 Mar; 64(3):323-9. PubMed ID: 16487444
[TBL] [Abstract][Full Text] [Related]
15. Thrombin activatable fibrinolysis inhibitor and other hemostatic parameters in patients with essential arterial hypertension.
Małyszko J; Tymcio J
Pol Arch Med Wewn; 2008; 118(1-2):36-41. PubMed ID: 18405171
[TBL] [Abstract][Full Text] [Related]
16. Coagulation Profile at Diagnosis in Patients with Acute Lymphoblastic Leukemia.
Sehgal S; Sharma S; Chandra J; Nangia A
Indian J Pediatr; 2016 Oct; 83(10):1082-6. PubMed ID: 27109393
[TBL] [Abstract][Full Text] [Related]
17. Plasminogen activator inhibitor-1 and thrombin activatable fibrinolysis inhibitor levels in non-alcoholic steatohepatitis.
Yener S; Akarsu M; Demir T; Akinci B; Sagol O; Bayraktar F; Ozcan MA; Tankurt E; Yesil S
J Endocrinol Invest; 2007 Nov; 30(10):810-9. PubMed ID: 18075282
[TBL] [Abstract][Full Text] [Related]
18. Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hypothyroidism.
Erem C; Ucuncu O; Yilmaz M; Kocak M; Nuhoglu I; Ersoz HO
Endocrine; 2009 Feb; 35(1):75-80. PubMed ID: 18958631
[TBL] [Abstract][Full Text] [Related]
19. Alterations of anticoagulant proteins and soluble endothelial protein C receptor in thalassemia patients of Chinese origin.
Huang Y; Long Y; Deng D; Liu Z; Liang H; Sun N; Xu Y; Lai Y; Cheng P
Thromb Res; 2018 Dec; 172():61-66. PubMed ID: 30384036
[TBL] [Abstract][Full Text] [Related]
20. Thrombin activatable fibrinolysis inhibitor and thrombin-antithrombin-III-complex levels in patients with gastric cancer.
Fidan E; Kavgaci H; Orem A; Yilmaz M; Yildiz B; Fidan S; Akcan B; Ozdemir F; Aydin F
Tumour Biol; 2012 Oct; 33(5):1519-25. PubMed ID: 22535370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]